Cited by 1,492Cancer Genomics and DiagnosticsColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Open access

Tie, Jeanne, Wang, Yuxuan, Tomasetti, Cristian, Li, Lu, Springer, Simeon, Kinde, Isaac, Silliman, Natalie, Tacey, Mark, Wong, Hui-Li, Christie, Michael, Kosmider, Suzanne, Skinner, Iain, Wong, Rachel, Steel, Malcolm, Tran, Ben, Desai, Jayesh, Jones, Ian, Haydon, Andrew, Hayes, Theresa, Price, Tim J., Strausberg, Robert L., Diaz, Luis A., Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Gibbs, Peter·2016·Science Translational Medicine

DOI 10.1126/scitranslmed.aaf6219PMC PMC5346159

Open this paper in CoChat — free account

Abstract

Detection of circulating tumor DNA in patients with resected stage II colon cancer provides evidence of residual disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aaf6219

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & PEPE, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,870
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Self-citation
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Self-citation
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Self-citation
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Sargent, D. J., Marsoni, S., Monges, G., Thibodeau, S. N., Labianca, R., Hamilton, S. R., French, A. J., Kabat, B., Foster, N. R., Torri, V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1825 · Cited by 1,623

Show all 43 references

Research works printed but not linked: 1

S. Edge D. R. Byrd C. C. Compton A. G. Fritz F. L. Greene A. Trotti AJCC Cancer Staging Manual (Springer New York 2010) 648 pp.

Sorted by citations

Items 901–1,000 of 1,001

Use of Molecular Assays and Circulating Tumor DNA in Early-Stage Colorectal Cancer: A Roundtable Discussion of the Gastrointestinal Cancer Therapy Expert Group
Loaiza‐Bonilla, A., Benson, A. B., Grothey, A. F., Karimi, M., Klempner, S. J., Lin, D., Mahtani, R. L., & Soares, H. P. (2021) · The Oncologist · doi:10.1002/onco.13738 · Cited by 8
Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels
Dhiman, A., Vining, C. C., Witmer, H. D. D., Sood, D., Shergill, A. P., Kindler, H. L., Roggin, K. K., Posner, M. C., Ahmed, O. S., Liauw, S. L., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11249-7 · Cited by 8
Towards a comprehensive framework for cell-free DNA analysis: lessons from TRACERx
Ulrich, B. C., & Guibert, N. M. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.12 · Cited by 8
High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant readsPreprint
Wan, J. C. M., Heider, K., Gale, D. G., Murphy, S., Fisher, E., Morris, J., Mouliere, F. C., Chandrananda, D., Marshall, A., Gill, A. B., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/759399 · Cited by 8
An intravenous DNA-binding priming agent protects cell-free DNA and improves the sensitivity of liquid biopsiesPreprint
Tabrizi, S., Martin-Alonso, C., Xiong, K., Blewett, T., Sridhar, S., An, Z., Patel, S., Rodriguez‐Aponte, S. A., Naranjo, C. A., Wang, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.13.523947 · Cited by 6
Assessment of postoperative circulating tumour DNA to predict early recurrence in patients with stage I–III right-sided colon cancer: prospective observational study
Lygre, K. B., Forthun, R. B., Høysæter, T., Hjelle, S. M., Eide, G. E., Gjertsen, B. T., Pfeffer, F., & Hovland, R. (2024) · BJS Open · doi:10.1093/bjsopen/zrad146 · Cited by 7
Factors associated with pathological complete remission after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a real-world clinical setting
Lin, M., Liu, J., Lan, C., Qiu, M., Huang, W., Liao, C., & Zhang, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1421620 · Cited by 8
Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more
Olivier, T., Haslam, A., Maravilla, D. O., Hernandez, E. F., & Prasad, V. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2024-000364 · Cited by 8
ctDNA/MRD Testing for Colon Cancer: A Work in Progress or Ready for Prime-Time Standard of Care?
Caughey, B. A., & Parikh, A. R. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7049 · Cited by 9
Digital sensing technologies in cancer care: A new era in early detection and personalized diagnosis
Yücel, M., Önder, A., Kurt, T., Keles, B., Beyaz, M., Karadağ, Y., Yaşyerli, İ., Celik, A. I., Sema, F., Tetik, S., et al. (2025) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2025.100651 · Cited by 10
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT
Pellatt, A. J., Bent, A. H., Hornstein, N. J., Parseghian, C. M., Huey, R. W., Raghav, K. P. S., Morris, V. K., Overman, M. J., Morelli, P., Willis, J. A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00142 · Cited by 9
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer
Brighi, N., Wetterskog, D., Vainauskas, O., Orlando, F., Ciani, Y., Gurioli, G., Conteduca, V., Casadei, C., Lolli, C., Giunta, E. F., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2121 · Cited by 7
From Early Detection To Advanced Therapies: How Circulating Tumor DNA Is Transforming the Care of Colorectal Cancer
Yee, E. J., McCarter, M. D., Vogel, J. D., Schulick, R. D., Lieu, C. H., & Lentz, R. W. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01725-8 · Cited by 8
Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series
Ji, H., Long, X., Gu, J., Jin, J., Mao, X., Wang, Z., Ma, H., & Chen, L. (2021) · Diagnostics · doi:10.3390/diagnostics11112055 · Cited by 7
Prognostic Value of Circulating Tumour DNA in Asian Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Liu, H., Yang, H. J., & Chen, X. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/8019652 · Cited by 7
Ready for ctDNA-guided treatment decisions in colorectal cancer?
Zhou, J., & Lin, G. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.003 · Cited by 8
Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer
Bonilla, C., Montenegro, P., O’Connor, J. M., Hernando, O., Aranda, E., Pinto-Llerena, J., Llontop, A., Escobar, J. G., Romero, M. D. C. D., Bautista-Hernández, Y., et al. (2023) · Cancers · doi:10.3390/cancers15174373 · Cited by 8
Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer
Xia, J., Zhang, J., Xiong, Y., Zhao, J., Zhou, Y., Jiang, T., & Zhu, J. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2252334 · Cited by 7
Clinical application of circulating tumor DNA in metastatic cancers
Raei, N., Safaralizadeh, R., & Latifi‐Navid, S. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2268008 · Cited by 8
Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management
Alnakli, A., Mohamedali, A., Heng, B., Chan, C., Shin, J., Solomon, M. J., Chapuis, P. H., Guillemin, G. J., Baker, M. S., & Ahn, S. B. (2024) · BJC Reports · doi:10.1038/s44276-024-00043-z · Cited by 8
ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach
Nielsen, L. R., Stensgaard, S., Meldgaard, P., & Sørensen, B. S. (2024) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2024.100802 · Cited by 7
Recent advances in DNA nanotechnology for cancer detection and therapy: A review
Esmaeilpour, D., Ghomi, M., Zare‬, E. N., & Sillanpää, M. E. T. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142136 · Cited by 9
Advances in colorectal cancer genomics and transcriptomics drive early detection and prevention
Lam, K. K., Thean, L. F., & Cheah, P. Y. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106032 · Cited by 7
Circulating tumor DNA dynamics analysis in a xenograft mouse model with esophageal squamous cell carcinoma
Terasawa, H., Kinugasa, H., Nouso, K., Yamamoto, S., Hirai, M., Tanaka, T., Takaki, A., & Okada, H. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i41.7134 · Cited by 7
Novel omics technology driving translational research in precision oncology
Basu, A., Budhraja, A., Juwayria, Abhilash, D., & Gupta, I. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.003 · Cited by 7
Research Progress on Postoperative Minimal/Molecular Residual Disease Detection in Lung Cancer
Wu, M., Shen, H., Wang, Z., Kanu, N., & Chen, K. (2022) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.10 · Cited by 7
ctDNA-guided adjuvant chemotherapy for colorectal cancer—ready for prime time?
Andersen, C. L., & Heitzer, E. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.017 · Cited by 7
Multifunctional Hybrid Nanozymes for Magnetic Enrichment and Bioelectrocatalytic Sensing of Circulating Tumor RNA during Minimal Residual Disease Monitoring
Koo, K. M. (2023) · Catalysts · doi:10.3390/catal13010178 · Cited by 7
Opportunities on the horizon for the management of early colon cancer
Knapen, D. G., de Haan, J. J., Fehrmann, R. S. N., de Vries, E. G. E., & de Groot, D. J. A. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103918 · Cited by 7
Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients
Warburton, L., Reid, A. L., Amanuel, B., Calapre, L., Millward, M., & Gray, E. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1280730 · Cited by 7
Molecular Approach to Colorectal Carcinoma
Beech, C. M., & Hechtman, J. F. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.08.011 · Cited by 7
Use of Circulating Tumor DNA to Guide Decision-making in Adjuvant Colon Cancer
Gottschalk, Z., & Cohen, S. A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01565-y · Cited by 7
JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis
Choi, M. Y., Kato, S., Wang, H., Lin, J. H., Lanman, R. B., & Kurzrock, R. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1450120 · Cited by 8
Use of circulating nucleic acids, metabolites, and proteins as clinical biomarkers for earlier prognosis and diagnosis of disease
Ananthamohan, K., Jha, R. M., & Sharma, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814259-2.00005-4 · Cited by 7
Cervical cytomegalovirus reactivation, cytokines and spontaneous preterm birth in Kenyan women
Begnel, E. R., Drake, A. L., Kinuthia, J., Matemo, D. N., Huang, M.-L., Ásbjörnsdóttir, K., Chohan, V., Beima‐Sofie, K., John-Stewart, G. C., Lehman, D., et al. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13558 · Cited by 8
ctDNA as a Prognostic Factor in Operable Colon Cancer Patients: A Systematic Review and Meta-Analysis
Yekedüz, E., Köksoy, E. B., Akbulut, H., Ürün, Y., & Utkan, G. (2020) · Future Oncology · doi:10.2217/fon-2020-0671 · Cited by 7
Perspectives for circulating tumor DNA in clinical management of colorectal cancer
Takemasa, I., Hamabe, A., & Ishii, M. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01937-5 · Cited by 7
Postoperative Circulating Tumor DNA Can Predict High Risk Patients with Colorectal Cancer Based on Next-Generation Sequencing
Lee, C. S., Kim, H. S., Schageman, J. J., Lee, I. K., Kim, M., & Kim, Y. (2021) · Cancers · doi:10.3390/cancers13164190 · Cited by 7
The impact of DNA testing on management of patients with colorectal cancer
Howe, J. R. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12526 · Cited by 6
Basic Science with Preclinical Models to Investigate and Develop Liquid Biopsy: What Are the Available Data and Is It a Fruitful Approach?
Cena, B., Melloul, E., Demartines, N., Dormond, O., & Labgaa, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105343 · Cited by 8
Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia
Cohen, J. D., Diergaarde, B. B., Papadopoulos, N., Kinzler, K. W., & Schoen, R. E. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0549 · Cited by 7
Self-citation
Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assayPreprint
Brannon, A. R., Jayakumaran, G., Diosdado, M. S., Patel, J., Razumova, A., Hu, Y., Meng, F., Haque, M., Sadowska, J., Murphy, B. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.27.175471 · Cited by 7
Self-citation
Undetectable circulating tumor DNA confirms the inability of pseudomyxoma peritonei to systemic dissemination
Villarejo‐Campos, P., Vazquez-Borrego, M. C., Martínez‐Quintanilla, J., Cabot, D., Romero‐Ruíz, A., Granados-Rodríguez, M., Bura, F. I., García‐Arranz, M., García‐Olmo, D., & Arjona‐Sánchez, Á. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108395 · Cited by 6
Prognostic Significance of the Comprehensive Biomarker Analysis in Colorectal Cancer
Potievskaya, V. I., Tyukanova, E. S., Sekacheva, M. I., Fashafsha, Z. Z. A., Fatyanova, A. S., Potievskiy, M. B., Kononova, E., Kholstinina, A., Polishchuk, E., Shegai, P., et al. (2025) · Life · doi:10.3390/life15071100 · Cited by 7
Molecular Residual Disease and Recurrence in Rectal Cancer Patients Undergoing Upfront Surgery
Ando, K., Hamabe, A., Nakamura, Y., Watanabe, J., Hirata, K., Kataoka, K., Miyo, M., Kato, K., Akazawa, N., Kagawa, Y., et al. (2025) · Annals of Surgery · doi:10.1097/sla.0000000000006948 · Cited by 8
Prognostic Value of Tumor-Informed Circulating Tumor DNA in HPV–Independent Head and Neck Squamous Cell Carcinoma
Ruiz‐Torres, D. A., Roberts, T. J., Du, P., Mendel, J., Neagele, S., Bonora, G., Zhang, F., Efthymiou, V., Merkin, R. D., Lin, D. T., et al. (2026) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2025.4837 · Cited by 6
Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework
Koo, K. M., Phillips, G., Srihari, S., Farrell, Á., Jaradi, B., Fitzpatrick, K. J., Yaxley, J. W., Samaratunga, H., Mainwaring, P. N., Ru, K., et al. (2026) · Advanced Science · doi:10.1002/advs.202512126 · Cited by 6
Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling
Martini, G., Napolitano, S., Ciardiello, D., Bielo, L. B., Martinelli, E., Troiani, T., Zampino, M. G., Fazio, N., Curigliano, G., & Ciardiello, F. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01126-1 · Cited by 6
Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis
Tang, M., Price, T. J., Shapiro, J. D., Gibbs, P., Haller, D. G., Arnold, D., Peeters, M., Segelov, E., Roy, A. C., Tebbutt, N. C., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1444481 · Cited by 6
Self-citation
Clinical Validity of Tumor-Informed Circulating Tumor DNA Analysis in Patients Undergoing Surgery of Colorectal Metastases
Hofste, L. S. M., Geerlings, M. J., Kamping, E. J., Kouwenhoven, N. D. H., von Rhein, D. T., Jansen, E. A. M., Garms, L. M., Nagtegaal, I. D., van der Post, R. S., de Wilt, J. H. W., et al. (2022) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002443 · Cited by 6
The potential role of minimal/molecular residual disease in colorectal cancer: curative surgery, radiotherapy and beyond
Xu, M., Shi, T., Xu, R., Chen, G., & He, W. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.05.005 · Cited by 6
Treatment and prognosis of colorectal cancer with synchronous peritoneal metastases: 11-year single institute experience
Qin, X., Yang, Z., Li, Y., Luo, J., Wang, H., & Wang, H. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100016 · Cited by 6
Current Status and Future Perspectives of Molecular Residual Disease Testing in Genitourinary Cancers
Kato, T., Yajima, S., Nakamura, Y., Kobayashi, S., & Miyake, H. (2025) · International Journal of Urology · doi:10.1111/iju.70215 · Cited by 6
Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer
Lam, M. S., Loree, J. M., Lima, A. A. P., Chun, Y. S., & Kopetz, S. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0524-2 · Cited by 6
Mutational landscape of circulating tumor DNA identifies distinct molecular features associated with therapeutic response in patients with metastatic colorectal cancer
Shi, M., Yuan, H., Ji, J., Zhang, S., Li, Q., Chen, Y., Gong, X., Zhu, Z., & Zhang, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211070643 · Cited by 6
High postoperative carcinoembryonic antigen as an indicator of high‑risk stage II colon cancer
Morimoto, Y., Takahashi, H., Arita, A., Itakura, H., Fujii, M., Sekido, Y., Hata, T., Fujino, S., Ogino, T., Miyoshi, N., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13287 · Cited by 6
Serial Circulating Tumor DNA in Monitoring the Effect of Neoadjuvant and Adjuvant Immunotherapy in Patients With Colon Cancer: Case Series and Review of the Literature
Qin, Q., Yang, K., Ma, T., Wang, H., Yu, P., Yuan, M., Chen, Y., & Wang, H. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000436 · Cited by 6
Harnessing Minimal Residual Disease as a Predictor for Colorectal Cancer: Promising Horizons Amidst Challenges
Wen, X., Coradduzza, D., Shen, J., Scanu, A. M., Muroni, M. R., Massidda, M., Rallo, V., Carru, C., Angius, A., & Miglio, M. R. D. (2023) · Medicina · doi:10.3390/medicina59101886 · Cited by 7
The diagnostic accuracy of local staging in colon cancer based on computed tomography (CT): evaluating the role of extramural venous invasion and tumour deposits
van den Berg, K., Wang, S., Willems, J., Creemers, G. J., Roodhart, J. M. L., Shkurti, J., Burger, J. W. A., Rutten, H. J. T., Beets‐Tan, R. G. H., & Nederend, J. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-04094-7 · Cited by 6
CD74 - ROS1 Fusion in NSCLC Detected by Hybrid Capture–Based Tissue Genomic Profiling and ctDNA Assays
Wang, V. E. H., Bivona, T. G., Ali, S. M., Schrock, A. B., & Miller, V. A. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2217 · Cited by 6
Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?
Morris, V. K., Dasari, A. N., & Kopetz, S. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0503 · Cited by 6
Development and Application of Duplex Sequencing Strategy for Cell-Free DNA (cfDNA)-Based Longitudinal Monitoring of Stage IV Colorectal Cancer.
Mallampati, S., Zalles, S., Duose, D., Hu, P. C., Medeiros, L., Wistuba, I. I., Kopetz, S., & Luthra, R. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.06.008 · Cited by 3
Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy
Malik, Y. G., Lyckander, L. G., Lindstrøm, J. C., Vinge-Holmquist, O., Sheikh, A. E., Schultz, J., & Ignjatović, D. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03381-w · Cited by 5
Die neoadjuvante und adjuvante Therapie des resektablen Kolonkarzinoms: Aktuelle Standards und Entwicklungen
Heinemann, V., & Stintzing, S. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1391-5124 · Cited by 6
Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer
Hayashi, T., Yoshida, Y., Yamada, T., Tanaka, K., Shimaoka, H., Kajitani, R., Munechika, T., Nagano, H., Matsumoto, Y., Komono, A., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4677 · Cited by 6
Liquid Biopsy im kolorektalen Karzinom
Haupts, A., Roth, W., & Hartmann, N. (2019) · Der Pathologe · doi:10.1007/s00292-019-00698-3 · Cited by 6
To Treat or Not to Treat: Adjuvant Therapy for Stage II Colon Cancer in the Era of Precision Oncology
Giannakis, M., & Ng, K. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.022103 · Cited by 6
Personalised surveillance after treatment for high-risk cancer
Guo, C. W., Lewin, J. H., & Shackleton, M. J. (2019) · Oncotarget · doi:10.18632/oncotarget.26619 · Cited by 6
Plasma-only ctDNA-Guided MRD Detection in Patients with CRC—Response
Parikh, A. R., & Corcoran, R. B. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3306 · Cited by 6
Monitoring circulating cell-free HPV DNA in metastatic or recurrent cervical cancer: clinical significance and treatment implicationsPreprint
Yin, Z., Feng, T., Xu, Q., Dai, W., Ni, M., Ni, J., & Lou, H. (2024) · eLife · doi:10.7554/elife.101887 · Cited by 6
Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX): Two-Year primary outcome analysis
Klebaner, D., Brown, E., Fisher, G. A., Shelton, A. A., Johnson, T. P., Shaheen, S., Chen, C. T., Heestand, G. M., Holden, T. L., Bien, J. Y., et al. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2025.110884 · Cited by 5
Long interspersed nuclear element 1 methylation in non-small cell lung cancer: implications for diagnosis, prognosis, and therapeutic targeting
Arachchillage, D. P. W., & Udomsinprasert, W. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02343-4 · Cited by 5
Circulating tumor DNA in Non-Viral head and neck squamous cell Carcinoma: A systematic review and Meta-Analysis
Helou, V., Abdul‐Rahman, N., Loo, S. K., Gao, S., Zevallos, J. P., Zandberg, D. P., Spector, M. E., Skinner, H. D., Ferris, R. L., & Contrera, K. J. (2025) · Oral Oncology · doi:10.1016/j.oraloncology.2025.107760 · Cited by 7
Dynamic Monitoring of Recurrent Ovarian Cancer Using Serial ctDNA: A Real-World Case Series
Rios‐Doria, E., Reichel, J. B., Radke, M. R., Manhardt, E., Rubin-Saika, M., Lockwood, C. M., Swisher, E. M., & Banda, K. (2025) · Current Oncology · doi:10.3390/curroncol32100585 · Cited by 5
Chemotherapy for patients with circulating tumour DNA-positive, stage II colon cancer (CIRCULATE)—an AIO/ABCSG trial
Folprecht, G., Stasik, S., Reinacher-Schick, A. C., Weiss, L., Goekkurt, E., Jacobasch, L., Conradi, L., Kröcher, A., Hofheinz, R. D., Liersch, R., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.05.001 · Cited by 6
Liquid biopsy can cure early colorectal cancer recurrence – Case Report
Baraniskin, A., Baba, H. A., Theegarten, D., Mika, T., Schroers, R., & Klein‐Scory, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1141833 · Cited by 5
Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit
Ochenduszko, S. L., Püsküllüoğlu, M., Pacholczak‐Madej, R., & Millo, O. R. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104443 · Cited by 5
NCI workshop on ctDNA in cancer treatment and clinical care
Sorg, B. S., Byun, J. S., Westbrook, V. A., Tricoli, J. V., Doroshow, J. H., & Harris, L. N. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae179 · Cited by 5
Challenges in blood fractionation for cancer liquid biopsy: how can microfluidics assist?
Salomon, R., Bazaz, S. R., Mutafopulos, K., Gallego‐Ortega, D., Warkiani, M. E., Weitz, D. A., & Jin, D. (2025) · Lab on a Chip · doi:10.1039/d4lc00563e · Cited by 5
Role of miR-214 in modulating proliferation and invasion of human colon cancer SW620 cells
Nie, H., Nie, D., & Men, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.9521 · Cited by 5
A Pipeline for ctDNA Detection Following Primary Tumor Profiling Using a Cancer-Related Gene Sequencing Panel
Nishizuka, S., Sato, K. A., & Hachiya, T. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9004-7_16 · Cited by 5
The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer
Beypınar, İ., Demir, H., Araz, M., Baykara, M., & Aykan, N. F. (2020) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-020-00542-5 · Cited by 4
Molecular Approach to Colorectal Carcinoma
Beech, C. M., & Hechtman, J. F. (2021) · Surgical pathology clinics · doi:10.1016/j.path.2021.05.007 · Cited by 5
Paired Comparison of Routine Molecular Screening of Patient Samples with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA Using Three Targeted Assays
Barthélémy, D., Lescuyer, G., Geiguer, F., Grolleau, E., Gauthier, A., Balandier, J., Raffin, M., Bardel, C., Bouyssounouse, B., Rodriguez‐Lafrasse, C., et al. (2023) · Cancers · doi:10.3390/cancers15051574 · Cited by 6
Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer
Xu, K., Yu, A.-R., Pan, S.-B., & He, J. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i36.5240 · Cited by 6
Assessment of aggressive bladder cancer mutations in plasma cell-free DNA
Carrasco, R., Ingelmo‐Torres, M., Oriola, J., Roldán, F. L., Rodríguez‐Carunchio, L., Herranz, S., Mellado, B., Alcaraz, A., Izquierdo, L., & Mengual, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1270962 · Cited by 5
Comprehensive genomic profiling of small bowel adenocarcinoma by tissue and plasma biopsy
Yu, D., Wang, J., Zheng, B. J., Yuan, M., Gu, D., Chen, R., & Chen, X. (2023) · Genomics · doi:10.1016/j.ygeno.2023.110766 · Cited by 5
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group
Rajdev, L. N., King, G. T., Lieu, C. H., Cohen, S. A., Pant, S., Uboha, N. V., Deming, D. A., Malla, M., Kasi, A., Klute, K. A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00489 · Cited by 6
Prognostic and Predictive Biomarkers in Nonmetastatic Colorectal Cancers
Haddad, F., Eid, R., Kourié, H. R., Barouky, E., & Ghosn, M. G. (2018) · Future Oncology · doi:10.2217/fon-2017-0708 · Cited by 5
Brain metastases in resected non-small cell lung cancer: The impact of different tyrosine kinase inhibitors
Yun, P.-J., Wang, G.-C., Chen, Y., Wu, T.-H., Huang, H., Lee, S.-C., Chang, H., & Huang, T.-W. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215923 · Cited by 6
Identification of circulating tumor DNA using a targeted 545‑gene next generation sequencing panel in patients with gastric cancer
Lan, J., Lu, Y., Guan, Y., Chang, L., Yu, Z., & Qian, H. (2020) · Oncology Letters · doi:10.3892/ol.2020.11305 · Cited by 5
The Role of Dynamic ctDNA Monitoring During Combination Therapies of BRAF V600E-Mutated Metastatic Colorectal Cancer: A Case Report
Wang, Z., Ye, C.-Y., Zhou, W., Wang, M., Dai, W.-P., Zheng, J., & Zang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s265725 · Cited by 5
Duration of adjuvant treatment for patients with stage III colon cancer
Koopman, M., & Punt, C. J. A. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30618-5 · Cited by 5
Clinical applications of circulating tumor-derived DNA in the management of gastrointestinal cancers – current evidence and future directions
Lam, R. C. T., Johnson, D., Lam, G., Li, M. L. Y., Wong, J. W. L., Lam, W. K., Chan, K. C. A., & Ma, B. B. Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.970242 · Cited by 5
Early detection of colorectal cancer somatic mutations using cfDNA liquid biopsies in a murine carcinogenesis model
Martínez-Gregorio, H., Díaz-Velásquez, C. E., Romero-Piña, M., la Cruz, M. R.-D., Delgado‐Buenrostro, N. L., Cruz-Montoya, A. H. D. L., Chirino, Y. I., Terrazas, L. I., Medina, L. A., & Vaca‐Paniagua, F. (2022) · Journal of Cancer · doi:10.7150/jca.76516 · Cited by 5
Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia
Moffitt, A. B., Spector, M. S., Andrews, P., Kendall, J., Alexander, J., Stepansky, A., Ma, B., Kolitz, J. E., Chiorazzi, N., Allen, S. L., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa090 · Cited by 5
Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019
Lau, D. K., Burge, M., Roy, A. C., Chau, I., Haller, D. G., Shapiro, J. D., Peeters, M., Pavlakis, N., Karapetis, C. S., Tebbutt, N. C., et al. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744439 · Cited by 5
Self-citation
Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome
Murray, N. P., C, R. V., Hartmann, D., Rodriguez, M. P., & Aedo, S. (2021) · Colorectal Disease · doi:10.1111/codi.15899 · Cited by 5
Refining the role of adjuvant chemotherapy in stage III colon cancer
Tanis, P. J. (2019) · Colorectal Disease · doi:10.1111/codi.14544 · Cited by 5
MAESTRO affords ‘breadth and depth’ for mutation testingPreprint
Gydush, G., Nguyen, E., Bae, J. H., Rhoades, J., Reed, S. C., Shea, D., Xiong, K., Liu, R., Blewett, T., Yu, F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.22.427323 · Cited by 5

Authors: Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., Kosmider, S., Skinner, I., Wong, R., Steel, M., Tran, B., Desai, J., Jones, I., Haydon, A., Hayes, T., Price, T. J., Strausberg, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Gibbs, P.
Affiliations: The University of Melbourne (AU)
Howard Hughes Medical Institute (US)
Johns Hopkins University (US)
PapGene (United States) (US)
The Royal Melbourne Hospital (AU)
Western Health (AU)
Walter and Eliza Hall Institute of Medical Research (AU)
Eastern Health (AU)
The Alfred Hospital (AU)
Department of Medical Oncology, Warrnambool Hospital, Warrnambool, Victoria 3280, Australia.
Department of Medical Oncology, Queen Elizabeth Hospital and University of Adelaide, Adelaide, South Australia 3174, Australia.
Ludwig Cancer Research (US)
Corresponding author: Tie, Jeanne
Wang, Yuxuan
Vogelstein, Bert
Gibbs, Peter
ORCID: Tie, Jeanne
Wang, Yuxuan
Tomasetti, Cristian
Li, Lu
Springer, Simeon
Silliman, Natalie
Tacey, Mark
Wong, Hui-Li
Christie, Michael
Kosmider, Suzanne
Skinner, Iain
Wong, Rachel
Steel, Malcolm
Tran, Ben
Desai, Jayesh
Jones, Ian
Haydon, Andrew
Hayes, Theresa
Diaz, Luis A.
Papadopoulos, Nickolas
Kinzler, Kenneth W.
Vogelstein, Bert
Gibbs, Peter
Venue: Science Translational Medicine
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2016-07-06
Volume: 8
Issue: 346
Pages: 346ra92-346ra92
ISSN: 1946-6234 (ISSN-L)
1946-6242
DOI: 10.1126/scitranslmed.aaf6219
PMC: PMC5346159
OpenAlex: W2460179076
Cited by: 1,492
References: 43
Citations by year: 2026: 119 · 2025: 131 · 2024: 130 · 2023: 181 · 2022: 173 · 2021: 197 · 2020: 173 · 2019: 146 · 2018: 134 · 2017: 90 · 2016: 14
FWCI: 53.29
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.sciencemag.org/about/science-licenses-journal-article-reuse (vor, 365 d)
Locations: Science Translational Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Funders: Virginia and D.K. Ludwig Fund for Cancer Research
Conrad N. Hilton Foundation
Sol Goldman Sequencing Facility at Johns Hopkins
NIH (CA57345, R37-CA43460, U01-CA152753, P30-CA006973)
Victorian Cancer Agency
Victorian Cancer Agency Clinical Research Fellowship
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: circulating tumor DNA, stage II colon cancer, minimal residual disease, tumor recurrence prediction, adjuvant chemotherapy, liquid biopsy, recurrence-free survival, plasma biomarkers, resected colon cancer
MeSH terms: Circulating Tumor DNA, Colonic Neoplasms, Humans, Neoplasm Recurrence, Local, Neoplasm Staging, Prospective Studies, Proportional Hazards Models, Neoplasm, Residual, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks